프랙틸 헬스(GUTS)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.60 (+1.56%), 시가총액 $0.14B, 52주 최저~최고 $0.39 ~ $2.88.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and chan
프랙틸 헬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
프랙틸 헬스의 현재 주가는 $0.60 (+1.56%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
프랙틸 헬스의 시가총액은 약 $0.14B입니다.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural ther